Stock comparison
Grifols
Eli Lilly
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GRFS
Grifols
Market cap
$6.75B
Sector
Healthcare
LLY
Eli Lilly
Market cap
$1T
Sector
Healthcare
Overall winner
Eli Lilly LLY
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GRFS | LLY | Winner |
|---|---|---|---|
| Warren Buffett | 59D | 72B | LLY |
| Benjamin Graham | 54C | 86A | LLY |
| Philip Fisher | 50C | 86A | LLY |
| Peter Lynch | 44D | 74B | LLY |
| Joel Greenblatt | 26F | 78C | LLY |
| Charlie Munger | 44D | 85A | LLY |
| Terry Smith | 47D | 77C | LLY |
Side-by-side metrics
| Metric | GRFS | LLY |
|---|---|---|
| Market cap | $6.75B | $1T |
| P/E (TTM) | 14.9x | 36.6x |
| EV/EBIT | 12.8x | 34.1x |
| ROIC (TTM) | 5.49% | 32.06% |
| Gross margin | 37.68% | 83.51% |
| Net margin | 5.58% | 34.98% |
| Revenue CAGR 5y | 10.02% | 23.17% |
| EPS CAGR 5y | 20.54% | 40.81% |
| Debt / Equity | 1.8x | 1.4x |
| Dividend yield | 1.65% | 0.62% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GRFS leads on
- EV/EBIT12.8xvs 34.1x+63%
- Dividend yield1.65%vs 0.62%+62%
- P/E (TTM)14.9xvs 36.6x+59%
LLY leads on
- Market cap$1Tvs $6.75B+99%
- Net margin34.98%vs 5.58%+84%
- ROIC (TTM)32.06%vs 5.49%+83%
- Revenue CAGR 5y23.17%vs 10.02%+57%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.